Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France. Show more
50 RUE DE DIJON, DAIX, FRANCE, 21121, Daix, 21121, USA
Market Cap
1.129B
52 Wk Range
$3.35 - $7.98
Previous Close
$4.84
Open
$4.63
Volume
1,350,616
Day Range
$4.60 - $4.86
Enterprise Value
926.7M
Cash
99.27M
Avg Qtr Burn
-54.26M
Insider Ownership
0.00%
Institutional Own.
41.80%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Lanifibranor (Pan-PPAR) Details Metabolic dysfunction-associated steatohepatitis (MASH) | Phase 3 Data readout | |
Lanifibranor + empagliflozin Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease, Type 2 diabetes | Phase 2a Update | |
Cedirogant (ABBV-157) (60RORy) Details Psoriasis, Kidney cancer, Carcinoma | Failed Discontinued | |
Odiparcil (GAG) Details Rare diseases, Rare genetic disease, Mucopolysaccharidoses, Mucopolysaccharidosis type IV, Genetic disorder | Failed Discontinued |
